Wirkstoffe & Arzneimittelsicherheit

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (11)

Wechselwirkungen · Abilify Maintena

Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre- filled syringe Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre- filled syringe · Abschnitt 4.5 · PDF-Seite 8

HOS-129416 · Präparat HOS-096717

Ketoconazole and other strong CYP3A4 inhibitors In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro- aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2). When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dose of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-28T15:16:00Z · SHA-256 41ea025269b746fee63511b9edbf4ea222d53988b45b27fd317f27f82cafb4fe · Passage e62cde9db823101aec4b3cf8dd070fc296f6271eadab6e46f40f9764eadd3552 · Zeichen 1323–2574 im Abschnitt

Wechselwirkungen · Abilify Maintena

Abilify Maintena 720 mg prolonged-release suspension for injection in pre-filled syringe Abilify Maintena 960 mg prolonged-release suspension for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 29

HOS-129450 · Präparat HOS-096717

Ketoconazole and other strong CYP3A4 inhibitors In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro- aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2). When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dose of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g., diltiazem) or CYP2D6 (e.g., escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-28T15:16:00Z · SHA-256 41ea025269b746fee63511b9edbf4ea222d53988b45b27fd317f27f82cafb4fe · Passage 7e0da39d4d12f55f8decbdfd4c36c1c9ff8062ade05a7c09d3e53a4bf51a0193 · Zeichen 1462–2715 im Abschnitt

Wechselwirkungen · Akynzeo

Akynzeo 300 mg/0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5

HOS-130696 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) citalopram (HOS-087802) duloxetine (HOS-089666) venlafaxine (HOS-086573) serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) fluvoxamine (HOS-085908) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 7496998149251e36b5a5979e551a8455c10917990713c719e5f50b629ca93bb4 · Zeichen 3396–3695 im Abschnitt

Wechselwirkungen · Akynzeo

Akynzeo 235 mg/0.25 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 21

HOS-130738 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Akynzeo

Akynzeo 235 mg/0.25 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 39

HOS-130781 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Akynzeo

Akynzeo 300 mg/0.5 mg oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 56

HOS-130817 · Präparat HOS-096947

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Aripiprazole Sandoz

Aripiprazole Sandoz 5 mg tablets Aripiprazole Sandoz 10 mg tablets Aripiprazole Sandoz 15 mg tablets Aripiprazole Sandoz 20 mg tablets Aripiprazole Sandoz 30 mg tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-133650 · Präparat HOS-097480

Ketoconazole and other CYP3A4 inhibitors In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63% and 37%, respectively. The AUC and Cmax of dehydro-aripiprazole increased by 77% and 43%, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors, may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-21T11:00:00Z · SHA-256 327ef54b8c9603e9d2d852929d852cc6b552a07adfbdb4be62ec8d86171c0375 · Passage 32947d7b07dd2edcee5beedb315cf63aef2da7b9d04ce0f619337d416755c0e1 · Zeichen 1520–2882 im Abschnitt

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19–20

HOS-134030 · Präparat HOS-097520

19 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas levels. co-administration with Genvoya Mean percent change in AUC, Cmax, Cmin1 Tricyclic antidepressants (TCAs) Interaction not studied with any of Careful dose titration of the Trazodone the components of Genvoya. antidepressant and monitoring for Selective serotonin reuptake antidepressant response is inhibitors (SSRIs) Concentrations of antidepressant recommended. Escitalopram agents may be increased when co-administered with cobicistat. IMMUNOSUPPRESSANTS Ciclosporin Interaction not studied with any of Therapeutic monitoring is Sirolimus the components of Genvoya. recommended upon Tacrolimus co-administration with Genvoya. Concentrations of these immunosuppressant agents may be increased when administered with cobicistat. SEDATIVES/HYPNOTICS Buspirone Interaction not studied with any of Co-administration of Genvoya and Clorazepate the components of Genvoya. triazolam is contraindicated (see Diazepam section 4.3). With other Estazolam Triazolam is primarily metabolised sedatives/hypnotics, dose reduction Flurazepam by CYP3A. Co-administration may be necessary and concentration Lorazepam with Genvoya may result in monitoring is recommended. Triazolam increased plasma concentrations of Zolpidem this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) lorazepam (HOS-085981) diazepam (HOS-085904) zolpidem (HOS-086327) serotonin (HOS-085477) trazodone (HOS-086251) tacrolimus (HOS-085202) buspirone (HOS-086325) sirolimus (HOS-085172) escitalopram (HOS-129417) triazolam (HOS-086168) flurazepam (HOS-086166)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 5942209e475c796ef61c4b0bb67f6fad6953705ca4043b5a69de6960506043d8 · Zeichen 46301–48689 im Abschnitt

Wechselwirkungen · Xospata

Xospata 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-141419 · Präparat HOS-098642

5HT2B receptor or sigma nonspecific receptor Based on in vitro data, gilteritinib may reduce the effects of medicinal products that target 5HT2B receptor or sigma nonspecific receptor (selective serotonin reuptake inhibitors e.g., escitalopram, fluoxetine, sertraline). Avoid concomitant use of these medicinal products with gilteritinib unless use is considered essential for the care of the patient.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477) sertraline (HOS-086247) fluoxetine (HOS-085946) escitalopram (HOS-129417)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-09T15:12:00Z · SHA-256 c553334e12e70f11f6e5ebf231d99102b822bac3002cf0bd26bc31c72e26836b · Passage 1303eefa2bbbc61d5477819574b1477da8b7f91437c34ee074bcd45a6788b099 · Zeichen 2602–3003 im Abschnitt

Wechselwirkungen · Cibinqo

Cibinqo 50 mg film-coated tablets Cibinqo 100 mg film-coated tablets Cibinqo 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-147565 · Präparat HOS-099686

In vitro, abrocitinib is an inhibitor of CYP2C19 enzyme. Co-administration of abrocitinib 200 mg once daily with omeprazole 10 mg single dose increased the AUCinf and Cmax of omeprazole by approximately 189% and 134%, respectively, indicating that abrocitinib is a moderate inhibitor of CYP2C19 enzyme. Caution should be exercised when using abrocitinib concomitantly with narrow therapeutic index medicines that are primarily metabolised by CYP2C19 enzyme (e.g. S-mephenytoin and clopidogrel). Dose adjustment may be required for other medicines primarily metabolised by CYP2C19 enzyme in accordance with their product information (e.g. citalopram, clobazam, escitalopram and selumetinib).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): selumetinib (HOS-145424) citalopram (HOS-087802) mephenytoin (HOS-109801) clopidogrel (HOS-087927) clobazam (HOS-115305) escitalopram (HOS-129417) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-16T15:51:00Z · SHA-256 bdf6a4ed1027bc748659bcb0a96655dbad2dd1f8fd77f49e5ad43eff208cc7ff · Passage 1cca7ac459e58966385e24e3af8466ce5a47e434584b749e74a0ba583d975299 · Zeichen 2955–3645 im Abschnitt

Wechselwirkungen · Etcamah

Etcamah 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-153231 · Präparat HOS-100955

Camizestrant in combination with ribociclib has been studied clinically, a non-fatal Torsades de Pointes was observed in a patient with bradycardia and QTc prolongation for camizestrant in combination with ribociclib. It is recommended to monitor patients clinically and adjust doses as specified in the approved ribociclib SmPC. Co-administration of other medicinal products known to prolong the QT interval and/or have a known risk of Torsades de Pointes (e.g. ciprofloxacin, levofloxacin, ondansetron, escitalopram, venlafaxine, fluconazole, chloroquine, halofantrine, clarithromycin, azithromycin, haloperidol, methadone, moxifloxacin, bepridil, and pimozide) should be avoided. If concomitant use cannot be avoided, monitor ECGs as clinically indicated (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) ciprofloxacin (HOS-085177) bepridil (HOS-085612) venlafaxine (HOS-086573) halofantrine (HOS-085606) azithromycin (HOS-088112) levofloxacin (HOS-128837) fluconazole (HOS-087945) clarithromycin (HOS-084517) pimozide (HOS-085600) moxifloxacin (HOS-085604) ribociclib (HOS-109454) camizestrant (HOS-153187) haloperidol (HOS-085602) ondansetron (HOS-086052) escitalopram (HOS-129417) chloroquine (HOS-109138)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T14:07:16Z · SHA-256 b50ea6ed7223cee8c2b96a46475d89e0843fb8c57083f80f60c2957e00e303a8 · Passage ce564d7e55982dc12152f2fbc04e0ebba5b06ca87263436e7452cbf8d84c3813 · Zeichen 6458–7234 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.